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Prolastin is a commercially available form of alpha-1-antitrypsin (AAT) that is derived from pooled human plasma and used
for treatment of severe alpha-1-antitrypsin deﬁciency (AATD). We describe a patient with AATD who developed presumed
hypersensitivity vasculitis (HV) following a Prolastin infusion. Hypersensitivity vasculitis (HV), or cutaneous vasculitis, is
characterized by inﬂammation of the small vessels of the skin with resultant ischemia to the distally supplied areas. To our
knowledge, this is the ﬁrst reported case of presumed hypersensitivity vasculitis following Prolastin infusion.
Copyright © 2009 N. W. Mwirigi and C. F. Thomas Jr. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.CaseReport
A-56-year old woman with a background history of type
2 diabetes, hypertension, GERD, severe asthma, COPD,
and newly diagnosed alpha-1-antitrypsin deﬁciency (AATD)
(ZZ phenotype) acutely developed shortness of breath and
fatigue following her ﬁrst Prolastin infusion. A week later
she received a second infusion with premedication. Over
the following 3 weeks the patient complained of a constel-
lation of symptoms including dyspnea, wheezing and one
episode of hemoptysis. She also complained of nonspeciﬁc
arthralgias and a diﬀuse rash. During this time she was
admitted to her home hospital where she was treated with
steroids and antibiotics (Augmentin). She did not improve
and was subsequently transferred to Mayo Clinic for further
evaluation.
The initial evaluation revealed the following: tempera-
ture, 37.0
◦C; blood pressure, 132/78; pulse rate, 73; oxygen
saturations, 98% on 3L/min nasal cannula; and respiratory
rate, 18. She was alert and oriented and sitting comfortably
in no apparent distress with a cushingoid appearance (due
to steroid use for chronic asthma and COPD). Physical
examrevealedmultiplepalpablepurpuricviolaceouspapules
coalescingintoserpiginousplaqueswithlargeadherentblack
eschars overlying her upper and lower extremities. Several
punched out ulcerations with yellow ﬁbrinous adherent
material were present over her bilateral upper thighs and
buttocks (Figure 1). Lung exam revealed bibasilar crackles.
Remainder of her exam was normal. A complete list of her
medications is included in Table 2.
Laboratory studies showed a normocytic anemia, slight
leucocytosis, elevated sedimentation rate, C-reactive protein,
and low AAT (Table 1). Urinalysis was unremarkable. CT
chest showed consolidative inﬁltrates in the left lower lung
posteriorly and scattered alveolar inﬁltrates throughout both
lungs. Bronchoscopy revealed old blood in the R lower lobe
subsegmental bronchus without any other endobronchial
lesions. BAL had a bloody return which cleared suggestive
of prior bleeding. Skin punch biopsy of the left lower leg
revealed mild superﬁcial dermal perivascular neutrophilic
inﬂammation.Directimmunoﬂuorescenceoftheskinbiopsy
was negative for deposits (IgG, IgM, IgA, C3, and ﬁbrinogen
all negative). She was treated with prednisone 60mg orally
once a day, dapsone 100mg by mouth orally once a day
for Pneumocystis jiroveci pneumonia prophylaxis as she had
a sulfonamide allergy, daily whirl pool therapy, and topical2 Case Reports in Medicine
(a) (b)
(c) (d)
Figure 1: Photographs of the vasculitic lesions on the lateral (a), posterior (b), and anterior aspects of the legs. Close-up of the large
ulceration on the lateral malleolus (d).
therapy with Sweitzer solution (zinc-boron-salicylate solu-
tion) and 0.1% triamcinolone cream. Her skin lesions and
associated symptoms continued to improve with treatment.
2. Discussion
Alpha-1-antitrypsin (AAT) is a 394 amino acid glycoprotein
produced by the liver and normally found in the serum
and extravascular locations, including the alveolar lining
of the lung. The main function of AAT is inhibition of
neutrophil elastase. If the quantity or functional activity
of AAT is signiﬁcantly reduced, the resulting imbalance
leaves the alveolar walls susceptible to proteolytic dam-
age, resulting in emphysema [1]. The association between
AATD and heritable emphysema was discovered in 1963
[2, 3]. Subsequent epidemiologic evidence suggested that a
serum AAT level of 11μmol/L (80mg/dL), which is 35%
of the normal level, represents a “threshold” value below
which the risk of developing emphysema is signiﬁcantly
increased [1]. The ability to isolate and purify the AAT
protein from human blood has made augmentation therapy
possible. Augmentation therapy has been shown to raise
antiprotease serum and epithelial lining ﬂuid levels above
the “protective threshold” value. Evidence suggests that this
approach slows the decline in lung function, could reduce
infection rates, might enhance survival, and is well tolerated
[4]. Based on available evidence, the American Thoracic
Society recommends augmentation therapy for individuals
with both a documented severe deﬁciency of AAT and ﬁxed
airﬂow obstruction [1]. Prolastin, a commercial preparation
of AAT from pooled blood, is given by intravenous infusion
at a dose of 60mg/kg ideal body weight once a week. The
largest cohort study in the USA looking at side eﬀects wasCase Reports in Medicine 3
Table 1: Pertinent laboratory tests.
Laboratory name Laboratory
Result Reference Ranges
Hemoglobin 11.0 13.5–17.5g/dL
Mean Corpuscle
volume 90.2 81.6–98.3FL
Leukocyte count 13.1 3.5–10.5×109/L
Platelet count 222 150–450 ×109/L
Creatinine 0.6 0.6–1.1mg/dL
Blood Urea Nitrogen 26 6–21mg/dL
Sedimentation rate 30 0–22mm/Lh
C-Reactive Protein 23.9 <= 8.0mg/L
Myeloperoxidase Ab <3.0 <6.0U/mL
Proteinase 3 antibody <3.0 <3.0U/mL
Cryoglobulin Negative
Cryoﬁbrinogen Negative
Complement total 63 30–75u/mL
Complement C1q 17 12–22mg/dL
C3 Complement 150 75–175mg/dL
C4 complement 20 14–40mg/dL
Antinuclear Ab 0.9 <= 1.0U
Anti DS DNA IgG <1.0 <5.0iu/mL
SS-A/RO Ab IgG <0.2 > or = 1.0U
SS-B/LA IgG 0.4 > or = 1.0U
Jo 1 Ab IgG 0.2 > or = 1.0U
Scl 70 Ab IgG <0.2 > or = 1.0U
Cyclic citrullated
peptide <15.6 <20 U
Anti glomerular
basement membrane <1.0 <= 20.9U
Alpha 1-anti-trypsin
level 23 100–190mg/dL
IgA 241 50–400mg/dL
Hepatitis B antibody Negative
Hepatitis Be antigen Negative
Hepatitis B antigen Negative
Hepatitis C antibody Negative
Hepatitis C RNA
detect/quant Negative
conducted by the National Heart Lung and Blood institute
(NHLBI)AATDRegistryGroup.Themostfrequentreported
side eﬀects include headache, dizziness, nausea, and dyspnea
[5]. Although acute allergic reactions, including anaphylaxis,
have been reported, these events are rare. It is important to
be aware that patients with severe AAT deﬁciency may also
be IgA deﬁcient and that Prolastin contains some IgA [5].
Possible diﬀerentials for this patient’s skin ﬁndings are
discussed below. Necrotizing panniculitis, which is charac-
terizedbyinﬂammatorylesionsoftheskinandsubcutaneous
tissue, is the major dermatologic manifestation of AATD [6–
9]. AATD individuals generally present with a hot, painful,
red subcutaneous nodule or plaque on the thigh or buttocks
[10]. These lesions can be diﬃcult to distinguish from
panniculitis due to other causes, but may be more inﬂam-
matory with an oily yellow discharge and more pronounced
histologic evidence of acute inﬂammation. Panniculitis is
the least common of the well-recognized complications of
AAT deﬁciency, with fewer than 50 cases reported in the
English literature [6, 9–13]. The prevalence among AAT-
deﬁcientsubjectsisprobablylessthanonecaseperthousand.
Panniculitishasbeenreportedtooccurinavarietyofpheno-
types, including PI
∗ZZ,PI
∗MZ,PI
∗SS, and PI
∗MS. Seventy
percent of reported cases have occurred in patients with
PI
∗ZZ phenotype and severe AAT deﬁciency [10]. Similar to
the pathophysiology of emphysema in such individuals, the
panniculitis is thought to result from unopposed proteolysis
in the skin. Deep excisional biopsies may be required to
establish the diagnosis. Characteristic histologic ﬁndings
include lobular fat necrosis of the lower reticular dermis,
with abundant neutrophil inﬂux interspersed with normal-
appearing fat and necrotic panniculus [14]. Based upon
this presumed pathophysiologic mechanism of unopposed
proteolysis, treatment of panniculitis in AATD subjects
has focused on restoring antiprotease activity. Intravenous
infusion of puriﬁed AAT has ameliorated the panniculitis
in some patients [7, 10]. Other treatments have included
dapsone (100mg/day for several weeks) and doxycycline
(200mg/day for as long as several months) [7, 10, 12]. The
latter is believed to act by scavenging reactive oxygen species
producedbyneutrophilsand/orbyslowingthebreakdownof
matrix proteins by elastase. Of note the appearance of these
skin ﬁndings in this case is not classic for panniculitis.
Wegener’s Granulomatosis, which is a systemic vasculitis
of the medium and small arteries and the venules and arteri-
oles, can have dermatological manifestations. These include
vesicular, palpable purpuric, ulcerative, and hemorrhagic
lesions. This patient’s presentation and clinical ﬁndings are
not compatible with the American College of Rheumatology
criteria for the classiﬁcation of Wegener’s granulomatosis
[15]. In particular, there was no upper airway involvement,
no evidence of granulomatous inﬂammation on her biopsy,
no abnormal urinary sediment or renal involvement, and
negative PR3 and MPO antibodies.
Likewise this patient’s presentation and ﬁndings are
not compatible with Churg-Strauss syndrome (CSS), also
called allergic granulomatosis and angiitis. This multisystem
disease is characterized by allergic rhinitis, asthma, and
prominent peripheral blood eosinophilia, none of which
were present in this case. Two-thirds of patients with CSS
have skin lesions, which usually appear as subcutaneous
nodules on the extensor surfaces of the arm, particularly
the elbows, hands, and legs [16]. The skin lesions can
appear as palpable purpura, macular or papular erythe-
matous rash, hemorrhagic lesions, ranging from petechiae
to extensive ecchymoses, tender cutaneous or subcuta-
neous nodules in which granulomas are usually found on
biopsy.
Hypersensitivity vasculitis (HV) or cutaneous vasculitis
is characterized by inﬂammation of the small vessels of
the skin with resultant ischemia to the distally supplied
areas [6]. In 1990 the American College of Rheumatology4 Case Reports in Medicine
Table 2: Outpatient Medications.
Medication Dose Frequency
Albuterol/ipratropium Q 4hrs as needed for SOB
Alprazolam 0.5mg by mouth Daily at bedtime
Ascorbic Acid 1000mg by mouth Daily at bedtime
Bupropion Unknown dose At bedtime
Calcium/Vitamin D 500mg/250 units by mouth Twice a day with meals
Fluticasone/Salmeterol 500/50 discus inhalation Twice a day
Furosemide 40mg by mouth Daily in am
Gabapentin 600mg by mouth in am, 600mg at noon, 1200mg at bedtime Three times a day
Glucosamine/Chondroitin 500mg/400mg by mouth Daily
Guaifenesin SR 600mg by mouth Twice a day
Ipratropium MDI Q 4–6hrs as needed
Loratadine 10mg (during allergy season) Daily
Magnesium oxide 400mg by mouth Daily with breakfast
Montelukast 10mg by mouth At bedtime
Multivitamin one tablet by mouth Daily in am
Nasonex 1 spray to each nostril At bedtime
Omega 3 1000mg by mouth Twice a day
Omeprazole 20mg by mouth Daily
Zoloft 100mg by mouth Daily
Sucralfate 1 gram by mouth Four times a day before meals and at bedtime
Verapamil SR 240mg by mouth Daily in am
proposed the following ﬁve criteria for the classiﬁcation of
hypersensitivity vasculitis:
(1) age >16,
(2) use of possible oﬀending drug in a temporal relation
to the symptoms,
(3) palpable purpura,
(4) maculopapular rash,
(5) biopsy of skin lesion showing neutrophils around an
arteriole or venule.
The presence of three or more of these criteria had
a sensitivity and speciﬁcity for the diagnosis of hypersen-
sitivity vasculitis of 71 and 84 percent, respectively [4].
Leukocytoclastic vasculitis (LV) is a histologic diagnosis.
It involves the deposition of immune complexes in vessel
walls, ultimately leading to cellular inﬁltrates, cytokine
release, and vessel damage. If IgA deposition is noted on
skin biopsy, it is necessary to rule out Henoch-Sch¨ onlein
purpura. Immunoﬂuorescence can be used if the skin biopsy
is inconclusive. Common causes of HV include drugs,
infections (HIV, hepatitis B and C), malignancy, connective
tissue disease (SLE, RA), and autoimmune disease. The most
common oﬀending drugs include antibiotics (penicillins,
cephalosporins,andmacrolides),loopandthiazidediuretics,
sulfonamides, allopurinol, and phenytoin [17]. The major
clinical ﬁndings of HV in addition to the skin lesions,
palpable purpura and/or petechia, include fever, urticaria,
arthralgias, lymphadenopathy, low serum complement lev-
els, and an elevated erythrocyte sedimentation rate. In most
patients, these symptoms and/or ﬁndings begin from 7 to 10
days after antigen exposure, the time required to produce a
suﬃcient quantity of antibody to produce antigen-antibody
complexes [18, 19]. However, the latent period may be
as short as two to seven days with a secondary antigen
exposure or longer than two weeks with a long-acting drug
such as benzathine penicillin [20]. The initial laboratory
work-up for evaluation of small vessel vasculitis has been
suggested to include complete blood count, erythrocyte
sedimentation rate, urinalysis, chemistry panel, stool guaiac,
ANA, ANCA, Rheumatoid factor (RF), cryoglobulins, C3,
C4, serology for hepatitis B and C, chest X-ray, and skin
biopsy [21]. Skin biopsy with specimens for routine light
microscopy and direct immunoﬂuorescence examination is
the ﬁrst step in determining whether authentic vasculitis
is present and excluding pseudovasculitic disorders (e.g.,
warfarin necrosis, cholesterol emboli). The choice and
timing of the biopsy will aﬀect diagnostic yields. Early
lesions, less than 48 to 72 hours old, are more likely to yield
neutrophilic vasculitis, whereas older lesions are more likely
to show a solely perivascular lymphocytic inﬁltrate without
evidence of vessel damage. Additional tests to consider
include blood cultures and echocardiography if the patient
has a high fever and/or has a heart murmur and anti-
streptolysin O titers in children [22]. The treatment options
include discontinuation of the inciting drug or antigen
which should lead to resolution of the signs and diagnosis
within a period of days to a few weeks. Conservative
measures include rest, leg elevation, support hoses, avoiding
cold exposure and tight ﬁtting clothes [23]. Treatment of
the underlying infection, such as the administration of
interferon and ribavirin to those with hepatitis C virus and
cryoglobulinemia, is recommended. In patients with moreCase Reports in Medicine 5
severe or persistent cutaneous disease not due to infection,
drugs such as colchicine, antihistamines, and dapsone may
be helpful [24–26]. Occasionally, combinations of these
drugs (e.g., dapsone and pentoxifylline) are more eﬀective
than single therapy [27]. Patients with complicated or
systemic disease in whom more toxic therapies are required
should be referred to a rheumatologist for consultation.
Immunosuppressive therapy with corticosteroids or cyto-
toxic agents should be reserved for the infrequent patient
with fulminant or progressive disease, some of whom may
have microscopic polyarteritis [26]. Novel therapy includes
TNF-alpha inhibitors, intravenous immunoglobulins, or
plasmapheresis[23].Rechallengeofthesuspecteddrugisnot
recommended.
Here we describe a patient who developed HV 2
weeks following her 2nd Prolastin infusion with fulminant
skin disease. As mentioned previously drugs are the most
common oﬀending agents, but drug-induced vasculitis is a
diagnosis of exclusion. It is hypothesized that drugs act as
haptens that cause an immune response. The most common
medications include antibiotics (penicillins, cephalosporins,
macrolides), antiretrovirals, granulocyte colony-stimulating
factor,loopandthiazidediuretics,sulfonamides,allopurinol,
and phenytoin [28]. Furosemide, a medication reported to
cause HV in a limited number of case based reports, was a
stable medication for this patient and therefore unlikely to
be implicated in her condition [29, 30]. Another important
factor to consider is that Prolastin contains trace amount
of polyethylene glycol (PEG), and other medications mixed
with PEG have been reported to cause HV (such as PEG
interferon for Hepatitis C). It is possible that this patient’s
reaction was secondary to the Prolastin preparation due
to PEG instead of the alpha-1-antitrypsin protein itself.
Zemeira, which is another preparation for AAT augmen-
tation, does not contain PEG and could be used if a
true reaction to PEG was veriﬁed. Due to the temporal
relationship of the rash with the Prolastin infusion and no
other new medications, we believe that the Prolastin is the
cause of the vasculitis. To our knowledge this is the ﬁrst
reported case of HV secondary to Prolastin administration.
Physicianand otherhealthcareprofessionalsshould beaware
of the possible rare adverse reaction using Prolastin.
Abbreviations
COPD: Chronic obstructive pulmonary disease
ANCA: Antineutrophil cytoplasmic antibody
TNF: Tumour necrosis factor
RF: Rheumatoid factor
AATD: Alpha-1-antitrypsin deﬁciency
AAT: Alpha-1-antitrypsin
HV: Hypersensitivity vasculitis
LV: Leukocytoclastic vasculitis
HIV: Human immunodeﬁciency virus
SLE: Systemic lupus erythematosus
RA: Rheumatoid arthritis
PeG: Polyethylene glycol
CSS: Churg-Strauss syndrome
SOB: Shortness of breathe.
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